| Metric | H2 FY26 | H1 FY26 | H2 FY25 |
|---|---|---|---|
| Revenue from operations | 167.2 | 64.6 | 57.8 |
| Other income | 3.5 | 2.3 | 2.7 |
| Total income | 170.7 | 67.0 | 60.5 |
| Profit before exceptional items & tax | 16.3 | 7.3 | 6.0 |
| Profit before tax | 16.3 | 7.3 | 6.0 |
| Net profit | 12.7 | 5.5 | 4.9 |
| Operating margin | 9.5% | 10.9% | 9.9% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +159.20% |
|---|---|
| Net profit, quarter on quarter | +130.90% |
| Revenue, year on year | +189.30% |
BSE results filing, BSE: 543916. Figures extracted from the filing.
Hemant Surgical Industries Ltd: key numbers
- Share price
- ₹665.20
- Market cap
- ₹867.3 Cr
- Revenue (annual)
- ₹231.8 Cr
- Net profit (annual)
- ₹19.19 Cr
- P/E (TTM)
- 45.2×Sector 53.1×
- Promoter holding
- 52.83%
- FII holding
- 0.14%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Hemant Surgical Industries Ltd
All →Hemant Surgical Industries Other Announcement
The company informs the exchange that it has sent letters to shareholders with unregistered email addresses, providing a weblink for the AGM Notice and Integrated Annual Report.
Hemant Surgical Industries Annual Report
Hemant Surgical Industries Ltd has filed its Integrated Annual Report and Notice of the 37th Annual General Meeting for the financial year 2025-26.
Hemant Surgical Industries Annual General Meeting
Hemant Surgical Industries Ltd has scheduled its 37th Annual General Meeting for September 29, 2026, to be conducted through video conferencing.
Hemant Surgical Industries Board Meeting Outcome
Hemant Surgical Industries approved its Directors' Report and Management Discussion and Analysis for FY2026, and scheduled its 37th Annual General Meeting for September 29, 2026.
Hemant Surgical Industries Announces New Order Win
Hemant Surgical Industries signed a manufacturing agreement with Sonomed Escalon, USA for ophthalmic ultrasound devices. The deal establishes local SKD manufacturing and exclusive distribution rights within India.
Hemant Surgical Industries Acquisition Worth ₹19.98 Cr
Hemant Surgical acquired a 66.66% stake in Lifesenz Cancer Research Labs for ₹19.98 Crore. The deal expands the company's footprint into the precision oncology segment.
- Value
- ₹19.98 Cr